Please assess the completion status of the following clinical trial:

Trial Title: Inflammation and Oxidative Stress of Adipose Tissue in Sleep Apnea Syndrome

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: BASIC_SCIENCE
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Male between 18 and 70 years old~* Apnea Hypopnea Index \> 30/h and \> 5% TST with SaO2 \< 90%~* patients obese (BMI \> 33kg/m2) or non obese (BMI \< 27kg/m2)~Exclusion Criteria:~* Female~* coronary ischemic disease, past history of CVA~* chronic pulmonary disease measured by arterial gasometry (PaO2 \< 60mmHg and/or PaCO2 \> 45mmHg)~* known hepatic disease~* alcohol consumption \> 3 units/day~* sleepiness considered to be dangerous by the investigator~* patient having an hazardous work regarding to awareness~* patient being under anticoagulant, antiplatelet drug or having an active stent or bleeding disorder~* patient having an inflammatory syndrome (C-reactive Protein \> 10)~* any allergy to local anaesthetics~* chronic muscle pain~* contraindication to MRI

- Gender: MALE
- Minimum Age: 18 Years
- Maximum Age: 69 Years
- Healthy Volunteers: f

Study Arms:
- obese + cPAP (Type: OTHER): Patients with sleep apnea syndrome will be first randomised in 2 arms according to their obesity. They will be secondly randomised in 2 arms receiving either cPAP treatment or Sham cPAP.
- obese + Sham cPAP (Type: OTHER): Patients with sleep apnea syndrome will be first randomised in 2 arms according to their obesity. They will be secondly randomised in 2 arms receiving either cPAP treatment or Sham cPAP.
- non-obese + cPAP (Type: OTHER): Patients with sleep apnea syndrome will be first randomised in 2 arms according to their obesity. They will be secondly randomised in 2 arms receiving either cPAP treatment or Sham cPAP.
- non-obese + Sham cPAP (Type: OTHER): Patients with sleep apnea syndrome will be first randomised in 2 arms according to their obesity. They will be secondly randomised in 2 arms receiving either cPAP treatment or Sham cPAP.

Based on this trial design, predict the completion outcome and termination type (if applicable).